Retrophin, LLC Announces Positive Results From Preclinical Studies of RE-024 for PKAN
3/11/2013 11:01:31 AM
NEW YORK--(BUSINESS WIRE)--Retrophin, Inc. (OTCQB: RTRX), a biotechnology company focused on the discovery and development of orphan drugs for the treatment of rare and life-threatening diseases for which there are currently no viable patient options, today announced positive results from a series of in vitro and in vivo experiments with RE-024. RE-024 rescued the phenotype of pantothenate kinase associated neurodegeneration (PKAN) in vitro and in vivo, demonstrating successful replacement therapy proof-of-concept.
comments powered by